The 2nd PhI­II schiz­o­phre­nia study for In­tra-Cel­lu­lar drug is a dis­as­ter, shares shred­ded

A year af­ter turn­ing up some mixed schiz­o­phre­nia da­ta from their first late-stage study of their lead drug for schiz­o­phre­nia, In­tra-Cel­lu­lar Ther­a­peu­tics to­day said that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER